PSTV PLUS THERAPEUTICS, INC.

Nasdaq plustherapeutics.com


$ 0.53 nm (nm)    

Thursday, 30-Oct-2025 19:52:09 EDT
QQQ $ 633.20 nm (nm)
DIA $ 475.83 $ -1.36 (-0.29 %)
SPY $ 684.43 nm (nm)
TLT $ 90.42 nm (nm)
GLD $ 371.67 nm (nm)
$ 0.5415
$ 0.55
$ 0.52 x 100
$ 0.56 x 1,200
$ 0.52 - $ 0.57
$ 0.16 - $ 2.31
4,884,717
na
72.84M
$ 1.31
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-30-2025 09-30-2025 10-Q
2 08-14-2025 06-30-2025 10-Q
3 05-30-2025 03-31-2025 10-Q
4 03-31-2025 12-31-2024 10-K
5 11-14-2024 09-30-2024 10-Q
6 08-14-2024 06-30-2024 10-Q
7 05-15-2024 03-31-2024 10-Q
8 03-05-2024 12-31-2023 10-K
9 10-31-2023 09-30-2023 10-Q
10 08-14-2023 06-30-2023 10-Q
11 04-20-2023 03-31-2023 10-Q
12 02-23-2023 12-31-2022 10-K
13 10-20-2022 09-30-2022 10-Q
14 07-21-2022 06-30-2022 10-Q
15 04-21-2022 03-31-2022 10-Q
16 02-24-2022 12-31-2021 10-K
17 10-21-2021 09-30-2021 10-Q
18 07-22-2021 06-30-2021 10-Q
19 04-22-2021 03-31-2021 10-Q
20 02-22-2021 12-31-2020 10-K
21 10-22-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-14-2020 03-31-2020 10-Q
24 03-30-2020 12-31-2019 10-K
25 11-14-2019 09-30-2019 10-Q
26 08-15-2019 06-30-2019 10-Q
27 05-14-2019 03-31-2019 10-Q
28 03-29-2019 12-31-2018 10-K
29 11-14-2018 09-30-2018 10-Q
30 08-14-2018 06-30-2018 10-Q
31 05-11-2018 03-31-2018 10-Q
32 03-09-2018 12-31-2017 10-K
33 11-09-2017 09-30-2017 10-Q
34 08-11-2017 06-30-2017 10-Q
35 05-12-2017 03-31-2017 10-Q
36 03-24-2017 12-31-2016 10-K
37 11-09-2016 09-30-2016 10-Q
38 08-05-2016 06-30-2016 10-Q
39 05-10-2016 03-31-2016 10-Q
40 03-11-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 plus-therapeutics-q3-eps-004-misses-002-estimate-sales-1397m-miss-1500m-estimate

Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $...

 d-boral-capital-maintains-buy-on-plus-therapeutics-maintains-5-price-target

D. Boral Capital analyst Jason Kolbert maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and maintains $5 price target.

 plus-therapeutics-expands-cnside-diagnostic-business-lands-national-coverage-deal-with-unitedhealthcare

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted rad...

 ascendiant-capital-maintains-buy-on-plus-therapeutics-raises-price-target-to-21

Ascendiant Capital analyst Edward Woo maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and raises the price target from ...

Core News & Articles

Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The ...

 why-merus-shares-are-trading-higher-by-38-here-are-20-stocks-moving-premarket

Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus fo...

 sp-500-falls-1-accenture-posts-upbeat-earnings

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Thursday. The Dow traded ...

Core News & Articles

Gainers PepGen (NASDAQ: PEPG) stock rose 114.3% to $5.7 during Thursday's regular session. The market value of their outst...

 nasdaq-down-over-1-us-initial-jobless-claims-fall

U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 1% on Thursday. Following the market open...

 d-boral-capital-maintains-buy-on-plus-therapeutics-maintains-5-price-target

D. Boral Capital analyst Jason Kolbert maintains Plus Therapeutics (NASDAQ: PSTV) with a Buy and maintains $5 price target.

Core News & Articles

Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session. The market value of their ...

 plus-therapeutics-announces-national-coverage-agreement-with-unitedhealthcare-for-cns-cancer-diagnostic-kit

CNSide Diagnostics, a wholly-owned subsidiary of Plus Therapeutics, Inc. (NASDAQ: PSTV), has signed a national agreement with U...

 d-boral-capital-maintains-buy-on-plus-therapeutics-maintains-5-price-target

D. Boral Capital analyst Jason Kolbert maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and maintains $5 price target.

 plus-therapeutics-secures-additional-19m-cprit-payment-under-176m-non-dilutive-grant

Non-dilutive payment is part of $17.6 million award granted for the Company's leptomeningeal cancer targeted radiotherapeut...

 d-boral-capital-maintains-buy-on-plus-therapeutics-maintains-5-price-target

D. Boral Capital analyst Jason Kolbert maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and maintains $5 price target.

 d-boral-capital-upgrades-plus-therapeutics-to-buy-announces-5-price-target

D. Boral Capital analyst Jason Kolbert upgrades Plus Therapeutics (NASDAQ:PSTV) from Hold to Buy and announces $5 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION